Analysts Set Amedisys Inc (AMED) PT at $79.20
Amedisys Inc (NASDAQ:AMED) has earned a consensus rating of “Buy” from the fifteen analysts that are presently covering the stock, Marketbeat reports. Three analysts have rated the stock with a hold recommendation, ten have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month price objective among brokerages that have issued a report on the stock in the last year is $79.20.
Several analysts recently issued reports on the company. ValuEngine raised Amedisys from a “hold” rating to a “buy” rating in a research note on Tuesday, May 8th. Zacks Investment Research raised Amedisys from a “hold” rating to a “buy” rating and set a $80.00 target price on the stock in a research note on Wednesday, May 9th. Royal Bank of Canada lifted their target price on Amedisys to $115.00 and gave the company an “outperform” rating in a research note on Friday, August 3rd. Craig Hallum lifted their target price on Amedisys from $60.00 to $82.00 and gave the company a “buy” rating in a research note on Wednesday, May 9th. Finally, TheStreet raised Amedisys from a “c+” rating to an “a-” rating in a research note on Monday, May 7th.
AMED traded up $0.76 on Wednesday, hitting $124.49. 295,854 shares of the company’s stock traded hands, compared to its average volume of 445,559. The company has a market capitalization of $3.88 billion, a PE ratio of 56.33, a price-to-earnings-growth ratio of 1.92 and a beta of 0.61. Amedisys has a one year low of $45.60 and a one year high of $125.10. The company has a current ratio of 1.21, a quick ratio of 1.21 and a debt-to-equity ratio of 0.30.
In other Amedisys news, major shareholder Kkr Credit Advisors (Us) Llc sold 2,437,424 shares of Amedisys stock in a transaction that occurred on Monday, June 4th. The stock was sold at an average price of $73.96, for a total value of $180,271,879.04. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, insider David B. Pearce sold 398 shares of Amedisys stock in a transaction that occurred on Wednesday, July 25th. The stock was sold at an average price of $94.18, for a total value of $37,483.64. Following the completion of the sale, the insider now directly owns 12,216 shares in the company, valued at approximately $1,150,502.88. The disclosure for this sale can be found here. In the last ninety days, insiders sold 2,457,201 shares of company stock worth $181,841,460. Corporate insiders own 2.60% of the company’s stock.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Itau Unibanco Holding S.A. bought a new position in shares of Amedisys during the 2nd quarter valued at approximately $149,000. SG Americas Securities LLC bought a new position in shares of Amedisys during the 1st quarter valued at approximately $123,000. Moneta Group Investment Advisors LLC bought a new position in shares of Amedisys during the 2nd quarter valued at approximately $181,000. Cubist Systematic Strategies LLC increased its position in shares of Amedisys by 1,086.0% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 2,372 shares of the health services provider’s stock valued at $203,000 after purchasing an additional 2,172 shares during the last quarter. Finally, Mount Yale Investment Advisors LLC bought a new position in shares of Amedisys during the 1st quarter valued at approximately $151,000. 98.37% of the stock is currently owned by hedge funds and other institutional investors.
Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and Personal Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses, physical and speech therapists, occupational therapists, and aides for its patients to complete their important personal tasks.
Featured Story: Should I invest in “strong buy” stocks?
Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.